eyestock logo

eyestock

IN

Ind Swift LtdNSE INDSWFTLTD

Последний отчетный период 30 сент., 2023

Обновлено 31 окт., 2024

Последняя цена

Капитализация млрд. $

0.003

Micro

Биржа

XNSE - National Stock Exchange Of India

Анализ акций INDSWFTLTD.NS

IN

Нет оценки

Количественный анализ Eyestock не покрывает акции Ind Swift Ltd.

Капитализация млрд. $

0.003

Дивидендная доходность

Оборот

54.165 млрд

Сайт компании

http://www.indswiftltd.com/

Ind-Swift Ltd. engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Chandigarh, Chandigarh. The firm operates in both domestic and export markets. The company is primarily engaged in the finished goods dosage and active pharmaceutical ingredients (APIs) and herbal products. The firm is also engaged in the hand sanitizer, face mask and personal protective equipment (PPE) kit market. The company operates through various divisions, such as Noble Division, Nova Division, Ethical Division, Generic Division, Institution Division and Proposed Division. Its Noble Division produces various products, such as Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin and Stemin Forte. The firm also provides a range of COVID19 products, including masks, travel kits, hand sanitizers, and gloves. The company has also launched two products, Stevia (natural sweetener) and Hangover (helps avoid alcoholic hangover). The firm also has five plants in India.

Смотреть Секцию: Рейтинг